Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...

With decades of hands-on experience, Sharp’s industry experts reveal their top five recommendations for a timely and ...

The promise of gene-editing therapies has passed the realm of scientific possibility to clinical reality. While DNA-altering treatments are considered relatively new and in the early commercial stages ...

Though the FDA will continue its core activities, the agency will no longer be accepting NDAs and BLAs until the ...

During HUAWEI CONNECT 2025, Leo Chen, Senior Vice President, President of Enterprise Sales, Huawei, emphasised the focus is on how to harness AI’s full potential.

Though unexpected CRLs issued by the FDA have caused ripples in the industry, Becky Wood believes that these cases are the ...

Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, adding microparticle capabilities ...

The US Government has shut down for the first time since 2018 after a majority of Democrat senators refused to back ...

As part of President Trump’s Most Favored Nation (MFN) policy, the company agreed to ensure that US patients are paying less for prescription medicines, with primary care treatments and some select ...

Orphan drugs are therapeutics developed to address rare diseases typically defined by patient population thresholds that vary across regions.

The Massachusetts bioresearch centre expansion is part of AbbVie’s wider ploy to bolster its US operations amid Trump tariff threats.

Changing trends in the biopharma sector may mean new risks for established players and opportunities for growth, says BIA ...